Retro Biosciences has raised $180M across 2 funding rounds. The latest round valued Retro Biosciences at $1.8B post-money, with 4P Capital on the lead line.
Retro Biosciences raised a Series B led by 4P Capital that valued the company at $1.8 billion, with the longevity startup saying its latest fundraising confirmed that valuation.
2 funding rounds, the latest highlighted.
Retro Biosciences was founded in 2021, United States.
A primary round — the company sells new shares to investors it selects. $180M raised, led by Sam Altman.
A primary round — the company sells new shares to investors it selects. Led by 4P Capital.
No filing has been made.
2 dated rounds, newest first.
Stripe, Y CombinatorThe last valuation is $1.8B.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Retro Biosciences is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
